Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma

Clinical Cancer Research

Volumn 21, Issue 1, 2015, Pages 175-183

  Gerami, Pedram ^a   Cook, Robert W ^b   Wilkinson, Jeff ^c   Russell, Maria C ^d   Dhillon, Navneet ^e   Amaria, Rodabe N ^f   Gonzalez, Rene ^f   Lyle, Stephen ^g   Johnson, Clare E ^b   Oelschlager, Kristen M ^b   Jackson, Gilchrist L ^h   Greisinger, Anthony J ⁱ   Maetzold, Derek ^b   Delman, Keith A ^d   Lawson, David H ^d   Stone, John F ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Castle Biosciences Incorporated   (United States)

^c ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CANCER TREATMENT CENTERS OF AMERICA   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^h Kelsey Seybold Clinic   (United States)

ⁱ Kelsey Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AQP3 GENE; ARG1 GENE; ARTICLE; BTG1 GENE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CLCA2 GENE; CONTROLLED STUDY; CRABP2 GENE; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC ANALYSIS; GJA1 GENE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; KRT6B GENE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; METASTATIC RISK; MGP GENE; MICROARRAY ANALYSIS; MULTICENTER STUDY; PREDICTIVE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S100A8 GENE; S100A9 GENE; SPRR1B GENE; TACSTD2 GENE; TYRP1 GENE; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MALE; MELANOMA; MIDDLE AGED; PATHOLOGY; RISK FACTOR; VERY ELDERLY;

TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84920538713     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3316     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010;28:2452-9.
4. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64:7205-9.
5. Francis P, Namlos HM, Muller C, Eden P, Fernebro J, Berner JM, et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007;8:73.
6. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
7. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol 2010;12:49-57.
8. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Richards WG, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003;95: 598-605.
9. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12:461-8.
10. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012;119:1596-603.
11. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-17.
12. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 2007;13:806-15.
13. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
14. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005;102:6092-7.
15. Mauerer A, Roesch A, Hafner C, Stempfl T, Wild P, Meyer S, et al. Identification of new genes associated with melanoma. Exp Dermatol 2011;20:502-7.
16. Scatolini M, Grand MM, Grosso E, Venesio T, Pisacane A, Balsamo A, et al. Altered molecular pathways inmelanocytic lesions. Int J Cancer 2010;126: 1869-81.
17. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Bio Ther 2005;4:1018-29.
18. Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, et al. Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 2004;23:2264-74.
19. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006;98:472-82.
20. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3.
21. Dhillon N, Rogers AR, Delman KA, Maetzold D, Oelschlager KM, Lyle S, et al. Gene expression profile signature (DecisionDx-Melanoma) to predict visceral metastatic risk in patients with stage I and stage II cutaneous melanoma. J Clin Oncol 30, 2012 (suppl; abstr 8543)."
22. Onken MD, Worley LA, Harbour JW. Association between gene expression profile, proliferation and metastasis in uveal melanoma. Curr Eye Res 2010;35:857-63.
23. Gokmen-Polar Y, Cook RW, Goswami CP, Wilkinson J, Maetzold D, Stone JF, et al. A gene signature to determine metastatic behavior in thymomas. PLoS One 2013;8:e66047.
24. Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, et al. A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol 2013;139:249-58.
25. Harbst K, Staaf J, Lauss M, Karlsson A, Ma˚sbäck A, Johansson I, et al. Molecular profiling reveals low- and high-grade forms of primary melanoma. Clin Cancer Res 2012;18:4026-36.
26. Koh SS, Wei JP, Li X, Huang RR, Doan NB, Scolyer RA, et al. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Mod Pathol 2012;25: 828-37.
27. Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J, et al. Gene expression profiling of paraf fi n-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 2009;15:6939-46.
28. Kashani-Sabet M, Venna S, NosratiM, Rangel J, Sucker A, Egberts F, et al. A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 2009;15:6987-92.
29. Abdel-Ghany M, Cheng HC, Elble RC, Pauli BU. The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem 2001;276:25438-46.
30. Cormier K, Harquail J, Ouellette RJ, Tessier PA, Guerrette R, Robichaud GA. Intracellular expression of inflammatory proteins S100A8 and S100A9 leads to epithelial-mesenchymal transition and attenuated aggressivity of breast cancer cells. Anticancer Agents Med Chem 2014; 14:35-45.
31. Grebhardt S, Muller-Decker K, Bestvater F, Hershfinkel M, Mayer D. Impact of S100A8/A9 expression on prostate cancer progression in vitro and in vivo. J Cell Physiol 2014;229:661-71.
32. Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, Mota LD, et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia 2009;11:1329-39.
33. Nakanishi H, Taccioli C, Palatini J, Fernandez-Cymering C, Cui R, Kim T, et al. Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene 2014;33:702-12.
34. Jin L, Zhang Y, Li H, Yao L, FuD, Yao X, et al. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis. Cell Res 2012;22:1356-73.
35. Meyer S, Fuchs TJ, Bosserhoff AK, Hofstädter F, Pauer A, Roth V, et al. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One 2012;7:e38222.